Lincoff A M, Topol E J
Department of Cardiology, Cleveland Clinic Foundation, OH 44195.
Circulation. 1993 Sep;88(3):1361-74. doi: 10.1161/01.cir.88.3.1361.
Thrombolytic therapy significantly improves the natural history of acute myocardial infarction, but recent data suggest that current reperfusion strategies have yet to realize the maximum potential for reduction of mortality and salvage of ventricular function. Coronary patency rates as high as 85% assessed by angiography 90 minutes after initiation of treatment greatly overestimate the efficacy of thrombolytic regimens, as this conventional angiographic "snapshot" view does not satisfactorily reflect the dynamic processes of coronary artery recanalization and reocclusion or the adequacy of myocardial perfusion. In fact, only the unusual patient appears to achieve optimal reperfusion for acute myocardial infarction, with a substantial deterioration of benefit in many patients due to insufficiently early or rapid recanalization, incomplete patency with TIMI grade 2 flow or critical residual coronary stenoses, absence of myocardial tissue reflow despite epicardial artery patency, intermittent coronary patency, subsequent reocclusion, or reperfusion injury. Recently developed techniques to critically assess the quality of reperfusion, coupled with the introduction of novel pharmacological agents and an improved understanding of the roles and mechanisms of existing thrombolytic and adjunctive drugs, have provided the opportunity to overcome many of the present limitations of reperfusion therapy. Emerging strategies to achieve optimal reperfusion are directed at enhancement of the velocity and quality of thrombolysis, amelioration of the adverse effects of reperfusion, and use of alternative pathways to myocardial salvage.
溶栓治疗显著改善急性心肌梗死的自然病程,但近期数据表明,目前的再灌注策略尚未充分发挥降低死亡率和挽救心室功能的最大潜力。治疗开始90分钟后通过血管造影评估的冠状动脉通畅率高达85%,这大大高估了溶栓方案的疗效,因为这种传统的血管造影“快照”视图不能令人满意地反映冠状动脉再通和再闭塞的动态过程或心肌灌注的充分性。事实上,只有极少数患者似乎能实现急性心肌梗死的最佳再灌注,许多患者因再通不够早或不够迅速、TIMI 2级血流的不完全通畅或严重的残余冠状动脉狭窄、尽管心外膜动脉通畅但心肌组织无再灌注、间歇性冠状动脉通畅、随后的再闭塞或再灌注损伤而使获益大幅下降。最近开发的严格评估再灌注质量的技术,加上新型药物的引入以及对现有溶栓药物和辅助药物的作用及机制的更好理解,为克服目前再灌注治疗的许多局限性提供了机会。实现最佳再灌注的新策略旨在提高溶栓的速度和质量、减轻再灌注的不良反应以及利用替代途径挽救心肌。